Medtronic (NYSE:MDT) announced today that reimbursement for its CGMs has been expanded or initiated across a number of countries.
Earlier this month, the Ontario, Canada provincial government announced a comprehensive reimbursement program for continuous glucose monitoring (CGM) for eligible residents who have type 1 diabetes, adding to a similar program for those with type 1 diabetes under 18 years old in Alberta, Canada.
At the end of 2021, the Colombian health benefit plan for 2022 was updated to include CGMs, making reimbursement no longer limited to approvals that were previously made on a case-by-case basis in the South American country, according to a news release.
Around the same time, in December 2021, the U.S. Centers for Medicare & Medicaid Services (CMS) expanded Medicare coverage for all kinds of CGMs, including those that integrate with Medtronic’s insulin pumps. At the time, analysts said that the new rule will likely bolster Medtronic’s Diabetes Business as a result of the expanded access to its diabetes technologies.
Finally, the company said that automated insulin pump reimbursement increased in Europe over the past several months, with Sweden reimbursing for the new Guardian 4 sensor with the MiniMed 780G system. Additionally, Croatia is fully reimbursing for the MiniMed 640G system with no limitations and reimbursing for MiniMed 780G with a copayment, while Estonia started reimbursement for 780G for people under 19 years old.
“It’s encouraging to see an increase in diabetes technology gaining reimbursement around the world,” Medtronic Diabetes VP of Health Economics, Reimbursement and Government Affairs Jeff Farkas said in the release. “We want people living with diabetes to have access to the therapies that best meet their diabetes management needs. Making it easier for people to get diabetes management technology helps improve control of this challenging disease and helps people live with less everyday worry about a chronic condition.”